INTRODUCTION
Neuropathic pain is likely to be multi-factorial and preclinical data from animal models of neuropathic pain suggest that in addition to spinal neuronal excitability, spinal microglial cells are also activated. Microglia cells are recognised as resident macrophages in the central nervous system and can release neuromodulatory transmitters that influence neuronal firing.
Peripheral nerve injury has been shown to increase the density of spinal microglia cells and alter microglial gene expression (McMahon and Malcangio, 2009 ). These changes occur in response to the increased peripheral sensory afferent input into the dorsal horn (Hathway et al., 2009; Suter et al., 2009) . Changes in microglial density and phenotype correlate with tactile allodynic behaviour in rats subjected to partial sciatic nerve injury (Coyle, 1998) or spared nerve injury (Suter et al., 2009 ) and in mice subjected to partial sciatic nerve ligation (Staniland et al., 2010) . Taken together, the data suggest that inhibiting microglial activation may be beneficial in the treatment of neuropathic pain.
The cysteine protease cathepsin S plays a role in maintaining microglia activity in pain states (Clark and Malcangio, 2012) . Cathepsin S is expressed by spinal microglia and becomes more abundant in response to nerve injury since the number of microglia increases (Clark et al., 2007) . Cathepsin S is released from microglia in response to nociceptive neurotransmitters such as ATP (Clark et al., 2010) and inhibitors of cathepsin S reverse mechanical allodynia and hyperalgesia in rodent models of neuropathic pain (Clark et al., 2007; Irie et al., 2008) .
The proposed target substrate for cathepsin S in the spinal cord is neuronal fractalkine. Dorsal horn preparations ex vivo show that liberation of soluble fractalkine is dependent upon cathepsin S (Clark et al., 2009 ) and mechanical allodynia evoked by spinal administration of exogenous cathepsin S is abolished in mice lacking the fractalkine CX3CR1 receptor (Clark et al., 2007) .
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Gabapentin and pregabalin exert analgesic effects in neuropathic pain states in humans such as post-herpetic neuralgia (Stacey and Glanzman, 2003; Gore et al., 2007) and diabetic neuropathy (Backonja et al., 1998) . The effects of gabapentin and pregabalin do not appear to be mediated by GABA receptors, but rather via inhibition of calcium currents mediated by calcium channels containing the α2-1 subunit (Fink et al., 2002; Sutton et al., 2002) .
Blockade of these channels leads to reduced release of pro-nociceptive neurotransmitters and attenuation of postsynaptic excitability in the spinal dorsal horn (Fehrenbacher et al., 2003; Takasusuki et al., 2011) .
Despite the efficacy displayed on clinical conditions, gabapentin and pregabalin have several drawbacks. Common side effects of gabapentin/pregabalin treatment include dizziness and sedation (Dworkin et al., 2010) and gabapentin/pregabalin provide substantial benefit in a minority of patients only (Moore et al., 2011) . Since neuropathic pain is multifactorial due to multiple pathways, enhanced pain relief is more likely to be achieved by combining compounds that affect pain transmission via different mechanisms of action (Raffa et al., 2010) .
MIV-247 is a selective, orally active inhibitor of cathepsin S designed for the treatment of 
MATERIALS AND METHODS

Enzyme assays
Cathepsin S from all species and cathepsin K were recombinant human enzymes expressed in For cathepsins S and V the substrate used was boc-Val-Leu-Lys-AMC, for non-rodent cathepsin K the substrate was H-D-Ala-Leu-AMC, for mouse cathepsin K the substrate was Z-Leu-Arg-AMC, for cathepsin L the substrate was H-D-Val-Leu-Lys-AMC, for cathepsin B the substrate was Z-Arg-Arg-AMC, for cathepsin H the substrate was H-Arg-AMC, for trypsin the substrate was Boc-Gln-Gly-Arg-AMC, for chymotrypsin the substrate was SuccAla-Ala-Pro-Phe-AMC, for human neutrophil elastase the substrate was Succ-Ala-Ala-ProVal-AMC. All substrates were from Bachem.
For cathepsin S the buffer was 100 mmol/L sodium phosphate, 100 mmol/L NaCl, 1 mmol/L DTT, 0.1% PEG 4000, pH 6.5. For cathepsin K the buffer was 100 mmol/L sodium phosphate, 5 mmol/L EDTA, 1 mmol/L DTT, 0.1% PEG 4000, pH 6.5. For cathepsin L the buffer was 100 mmol/L sodium acetate, 1 mmol/L EDTA, 1 mmol/L DTT, 0.1% PEG 4000, pH 5.5. For cathepsin B the buffer was 50 mmol/L sodium phosphate, 1 mmol/L EDTA, pH 6.25. For cathepsin H the buffer was 100 mmol/L tris-acetate, 1% PEG4000, pH 7.5. For cathepsin V the buffer was 25 mmol/L sodium acetate, 2.5 mmol/L EDTA, pH 5.5. For trypsin, chymotrypsin and human neutrophil elastase the buffer was 50 mmol/L HEPES, 100 mmol/L NaCl, 10 mmol/L CaCl 2 , 0.1% CHAPS, pH 8.0.
All experiments were carried out in accordance with UK Home Office Regulations (Animal Scientific Procedures Act, 1986) . Male C57/BL6 mice (25-30 g), obtained from Harlan UK, were used in partial nerve ligation and beam walking experiments. The animals were housed in groups of 5 under a 12 h light/dark cycle (lights on at 7.00 a.m.) with food and water ad libitum. Animals were allowed to habituate for at least 5 days prior to surgery or experiments.
Male C57/BL6 mice (20-30 g), obtained from Taconic, Denmark, were used in the pharmacokinetic studies. The animals were housed (max 5 animals/cage) with food and water ad libitum. Fluorescent lighting with 12 h light and 12 h dark cycle was used, and the animals were allowed to habituate for at least 5 days prior to the experiments.
Surgery -partial nerve ligation
Mice were anaesthetised with isoflurane 2% O 2 mixture maintained during surgery via a nose cone. After surgical preparation the common sciatic nerve was exposed at the middle of the thigh by blunt dissection through biceps femoris. Proximal to the sciatic trifurcation, about 7 mm of nerve was freed of adhering tissue and one third to one half of the dorsal aspect of the nerve was ligated (5-0 silk) (according to Seltzer et al., 1990 , as adapted to mice by Malmberg and Basbaum, 1998), then the incision was closed in layers.
Assessment of mechanical withdrawal thresholds
Mechanical thresholds of the ipsilateral (left) paw and contralateral (right) paw were assessed before surgery and on days 3, 5, 7 and 10 after surgery to ascertain the development of mechanical allodynia (assessed as the difference in thresholds between contra and ipsilateral paws). Animals were transferred to the experimental room on the test day and allowed to acclimatise in acrylic cubicles (8 x 5 x 10 cm) atop a wire mesh grid for up to 60 min prior to testing. Static mechanical withdrawal thresholds were assessed by applying calibrated von Frey hairs (flexible nylon fibres of increasing diameter that exert defined levels of force;
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Touch Test; Stoelting, USA) to the plantar surface of the hind paw until the fibre bent. The hairs were held in place for 3 s or until the paw was withdrawn, the latter defining a positive response. Starting with a stimulus strength of 0.07 g, hairs were applied according to the 'updown' method within a range of 0.008 g -1.0 g and from this 50% paw withdrawal thresholds (PWT) were calculated (Dixon, 1980; Chaplan et al., 1994) . All experiments were carried out by an observer blinded to drug treatments.
Animals were considered allodynic when they displayed a response of 0.1 g or less, normal responses are from 0.6 g -1 g. From day 11 after surgery approximately 80% of the mice developed allodynia and were randomised into groups. Paw withdrawal thresholds were assessed before and at 1, 3 and 6 h post dosing of compound or vehicle.
The raw 50% PWT data was used for statistical analysis (see below). For simplicity and comparision, effects of compounds were expressed as % reversal using the following formula:
% reversal
Ipsilateral 50% PWT compound Ipsilateral 50% PWT vehicle Contralateral 50% PWT compound Ipsilateral 50%PWT vehcile
Beam walking
The risk of pregabalin, gabapentin or MIV-247 exerting possible dizziness or ataxia behaviour was assessed in normal (non-injured) C57BL/6 mice using a beam walking test (Stanley et al., 2005 
Pharmacokinetic data
Pharmacokinetic data was generated in two separate studies where C57BL/6 male mice were administered MIV-247, pregabalin, gabapentin, a combination of MIV-247 and pregabalin or a combination of MIV-247 and gabapentin. Three mice were included in each group and the doses were 100 µmol/kg, 75 µmol/kg and 146 µmol/kg for MIV-247, pregabalin and gabapentin, respectively. The dose volume was 5 mL/kg for each compound.
Compounds
MIV-247 was synthesised by Medivir AB (Huddinge, Sweden), formulated in 20%
hydroxypropyl-β-cyclodextrin in water and given via oral gavage at a dose volume of 5 mL/kg at doses up to 200 µmol/kg. The molecular structure of MIV-247 is shown in Figure 1 .
The synthesis description of MIV-247 can be found in Supplemental file 1.
Gabapentin was purchased from Toronto Research Chemicals Inc., dissolved in distilled water, and given via oral gavage at a dose volume of 5 mL/kg at doses up to 584 µmol/kg.
Pregabalin was purchased from Tocris Bioscience, dissolved in distilled water, and given via oral gavage at a dose volume of 5 mL/kg at doses up to 377 µmol/kg.
Measurement of MIV-247, gabapentin and pregabalin concentrations
This article has not been copyedited and formatted. The final version may differ from this version. In some cases, blood was withdrawn from euthanized neuropathic mice immediately after the experiments (i.e. ~6 h post-dose) by heart puncture into pre-chilled heparinised tubes. Blood samples were immediately put on ice prior to centrifugation. Plasma was prepared by centrifugation for 10 min at approximately 1,000 g at +4 ºC within 10 min from sampling.
Plasma samples were stored at -20 ºC prior to analysis. Brain and spinal cord were dissected and snap-frozen in liquid nitrogen and stored at -20 ºC prior to analysis.
In the pharmacokinetic studies, seven blood samples (~20 µL) were drawn from the lateral 
Pharmacokinetic calculations
The pharmacokinetic (PK) data analysis was performed using the software WinNonlin, version 5.3 (Pharsight Corporation, CA, USA). The PK data of MIV-247, pregabalin and gabapentin was analyzed using non-compartmental methodology.
The following PK parameters were reported:
• The area under the plasma concentration vs. time curve (AUC0-t) from time zero to time t was calculated by the log/linear trapezoidal method. The last sampling timepoint was 7 h post dose. AUC0-t was extrapolated to infinity (AUC0-inf) by adding Clast/λz, where Clast is the last measurable plasma concentration and λz is the terminal elimination rate constant.
• Maximal plasma concentration (C max )
• Time at maximal concentration (T max )
• The terminal half-life (t ½ )
The half-life was calculated as In2/λz, where λz is the elimination rate constant. The half-life was only calculated if at least 3 data-points could be included in the regression and the r 2 for the regression was >0.80.
Statistical analysis
Mechanical thresholds in neuropathic pain studies were expressed as 50% paw withdrawal threshold (50% PWT) in grams (g) and statistically analysed by Repeated Measure (RM) 
RESULTS
Characterization of MIV-247 pharmacology in vitro
MIV-247 had a mean K i (dissociation constant) value of 2.1 nmol/L for human cathepsin S and was highly selective vs. other related cathepsins (Table 1) . MIV-247 was also a potent inhibitor of mouse and cynomolgus monkey cathepsin S with K i values of 4.2 nmol/L and 7.5 nmol/L, respectively (Table 1) , while having moderate potency against mini-pig and dog cathepsin S. In the rat there is an important difference in the S2 pocket between strains. In human, cathepsin S residue 137 is a glycine, while this residue is a cysteine (G137C) in wildtype Sprague-Dawley and Wistar rat strains commonly used in preclinical research (Irie et al., 2008) . This probably explains the 10,000-fold loss in potency on rat cathepsin S ( Table 1 ).
The reversibility of MIV-247 binding to human cathepsin S was evaluated. Taken together, the data generated in vitro suggest that MIV-247 is a potent, selective and reversible human cathepsin S inhibitor with similar potency against mouse cathepsin S while displaying 10,000-lower potency against rat cathepsin S. Hence, mice were the chosen species for in vivo pharmacology.
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Effect of MIV-247 on PNL-evoked allodynia
Single oral dosing of MIV-247 attenuated mechanical allodynia in mice in a dose-dependent manner from 100 to 200 µmol/kg ( Fig. 2A) . A dose of 100 µmol/kg MIV-247 transiently attenuated mechanical allodynia while a dose of 200 µmol/kg MIV-247 resulted in sustained significant efficacy lasting at least 6 h. The maximal anti-allodynic effect of 200 µmol/kg MIV-247 (52% reversal of allodynia, p < 0.01) was reached at 6 h post dose. A higher dose of 500 µmol/kg MIV-247 resulted in similar, but not higher, anti-allodynic efficacy (data not shown). Contralateral thresholds were not affected by MIV-247 at any dose (Fig. 2B ).
Repeated oral dosing of MIV-247 (twice daily for 5 days) also attenuated mechanical allodynia in a dose-dependent manner when measured at 3 h post-dose in the morning (Fig.   2C ). Significant reversal (ranging between 36-49%) was observed compared to vehicle on all days following oral administration of MIV-247 at the dose of 200 µmol/kg. The lower dose of 100 µmol/kg MIV-247 also affected mechanical allodynia and a significant effect was recorded on day 3 of the study (32% reversal, p < 0.05).
Effect of pregabalin and gabapentin on PNL-evoked allodynia
Single oral dosing of pregabalin and gabapentin attenuated mechanical allodynia in a dosedependent manner (Figs. 3A and B) . Doses of 188 and 377 µmol/kg (equivalent to 30 and 60 mg/kg) pregabalin resulted in sustained efficacy lasting at least 6 h (Fig. 3A) , but a dose of 63 µmol/kg (10 mg/kg) was without effect. A dose of 350 µmol/kg gabapentin (60 mg/kg) resulted in sustained efficacy, while a dose of 175 µmol/kg (30 mg/kg) gabapentin resulted in transient efficacy lasting 1 h (Fig. 3B) . The lowest dose of gabapentin (58 µmol/kg, 10 mg/kg) was without effect. The contralateral thresholds were not affected by pregabalin or gabapentin (data not shown).
Effect of MIV-247 and pregabalin in combination on PNL-evoked allodynia
This article has not been copyedited and formatted. The final version may differ from this version. Minimum effective doses of MIV-247 and pregabalin were evaluated alone and in combination (Fig. 4A ). MIV-247 (100 µmol/kg p.o.) and pregabalin (75 µmol/kg p.o.), when given alone, transiently attenuated mechanical allodynia. The effect of MIV-247 was nonsignificant (22% and 29% reversal at 1 h and 3 h, respectively) while the effect of pregabalin was significant at 1 h post-dose (28% reversal, p < 0.05) but not at 3 h post dose (32% reversal, p > 0.05). When combining these compounds at the indicated doses, significant and prolonged anti-allodynic efficacy was observed with 51%, 81% and 33% reversal at 1 h, 3 h and 6 h post-dose, respectively.
Sub-effective doses of MIV-247 and pregabalin were evaluated alone and in combination (Fig. 4B ). Neither MIV-247 (50 µmol/kg p.o.) nor pregabalin (38 µmol/kg p.o.) when given alone had any effect on mechanical allodynia. When combining these compounds at the indicated doses, significant anti-allodynic efficacy with 35% reversal was observed at 3 h post-dose.
Effects of MIV-247 and gabapentin in combination on PNL-evoked allodynia
Minimum effective doses of MIV-247 and gabapentin were evaluated alone and in combination (Fig. 5A ). MIV-247 (100 µmol/kg p.o.) and gabapentin (146 µmol/kg p.o.), when given alone, transiently attenuated allodynia 1 -3 h post-dose. The effects of MIV-247
were not statistically significantly different from controls (22% reversal, p < 0.05) while the effect of gabapentin was significant only at the 3 h post-dose time point (34% reversal, p < 0.05). When combining these compounds at the indicated doses, significant anti-allodynic efficacy was observed for up to 8 h post-dose with 48%, 85%, 61% and 35% reversal at 1, 3, 6 and 8 h post-dose, respectively. The effect of the combination had subsided at 24 h postdose.
This article has not been copyedited and formatted. The final version may differ from this version. Sub-effective doses of MIV-247 and gabapentin were evaluated alone and in combination (Fig. 5B) . MIV-247 (50 µmol/kg p.o.) and pregabalin (73 µmol/kg p.o.) had no significant effects on allodynia when given alone as expected. When combining these compounds at the indicated doses, significant anti-allodynic efficacy with 56%, 68%, and 41% reversal at 1, 3, and 6 h post-dose was seen.
Effects of minimum effective doses of MIV-247 and pregabalin on beam walking
As expected, 584 µmol/kg (100 mg/kg) gabapentin p.o., serving as a positive control, induced a significant increase in the number of foot slips at 1 h and 3 h post dose in normal, noninjured mice (Fig. 6A) . Minimal effective doses of MIV-247 (100 µmol/kg, p.o.) or pregabalin (75 µmol/kg, p.o.) or their combination did not affect the number of slips compared to vehicle (Fig. 6A) . Hence, the enhanced anti-allodynic effects exerted by combining MIV-247 and pregabalin were most likely not associated with behavioural changes consistent with dizziness or ataxia.
Effects of minimum effective doses of MIV-247 and gabapentin on beam walking
As expected, 584 µmol/kg (100 mg/kg) gabapentin p.o., used as a positive control, induced a significant increase in the number of foot slips at 1 h and 3 h post dose (Fig. 6B) . Minimal effective doses of MIV-247 (100 µmol/kg, p.o.) or gabapentin (146 µmol/kg, p.o.) or their combination did not affect the number of slips compared to vehicle (Fig. 6B) . Hence, the enhanced anti-allodynic effects exerted by combining MIV-247 and gabapentin were most likely not associated with behavioural changes consistent with dizziness or ataxia.
Concentrations of MIV-247, pregabalin and gabapentin when given alone or in combination
The plasma concentrations of MIV-247 and pregabalin when given alone or in combination at minimal effective doses in satellite, non-injured mice are shown in Fig. 7A . The either compound compared to when the compounds were given separately. The pharmacokinetic parameters for these experiments are given in Table 2 .
Although not systematically measured in every experiment, the data in hand suggest that the concentrations of the different compounds in the brain and spinal cord did not appear to differ either when given alone or in combination. Table 3 shows plasma, brain and spinal cord concentrations of MIV-247 and pregabalin at 3.5 h post-dose when given at sub-effective doses to satellite mice. Table 4 shows plasma, brain and spinal cord concentrations of MIV-247 and gabapentin at 3 h post-dose when given at minimum effective doses to satellite mice and concentrations at 6 h post-dose when given to neuropathic mice. Similar concentrations were present when compounds were given separately or in combination. The ratios between brain and plasma or spinal cord and plasma concentrations were similar for all MIV-247, pregabalin and gabapentin when administered alone or in combination.
DISCUSSION
The current study demonstrates in a mouse model of neuropathic pain that cathepsin S inhibition per se, using the orally active, highly potent and selective inhibitor MIV-247, attenuates mechanical allodynia without any detectable behavioural side effects in mice.
Enhanced anti-allodynic efficacy was observed when combining MIV-247 with gabapentin or pregabalin without evoking additional side effects and without any detectable pharmacokinetic interactions. Hence, combination of the selective cathepsin S inhibitor MIV-247 with pregabalin or gabapentin represents a means of increasing both efficacy and therapeutic window.
MIV-247 was slightly more potent than gabapentin at reversing mechanical allodynia while being slightly less potent than pregabalin when given orally. A dose of 100 µmol/kg MIV-247 was required for a minimum anti-allodynic effect vs. 146 µmol/kg gabapentin and 75 µmol/kg pregabalin. The rank order of potency was different when comparing the plasma levels required for minimal efficacy. Minimal effective doses of MIV-247 gave rise to plasma levels of 8-12 µmol/L x h while the corresponding exposures for gabapentin and pregabalin were 68-69 and 86-92 µmol/L x h, respectively. Interestingly, a C max of approximately 16 µmol/L gabapentin is reached in man at 3 h post-dose in response to 300 mg gabapentin (Chang et al., 2014) , while a C max of approximately 40 µmol/L pregabalin is reached in man at 1 h post-dose in response to 200 mg pregabalin (Brodie et al., 2005) . This is similar to the plasma levels of gabapentin and pregabalin reached in our study at minimum effective doses (Table 2) suggesting that the exposure of gabapentin in the current study is of clinical relevance. It is thus tempting to speculate that the same degree of efficacy could be reached at lower plasma levels of gabapentin or pregabalin when given together with MIV-247, thereby widening the therapeutic window (see discussion below). However, clinical studies will be needed to prove a role for cathepsin S in neuropathic pain and the mechanical allodynia endpoint used in the Table 4 demonstrates that sub-effective threshold doses of MIV-247 gave rise to 0.1 -0.2 µmol/L concentrations in the spinal cord and brain while corresponding levels for pregabalin were 2 -3 µmol/L. This superior potency is perhaps not surprising since MIV-247 has a Ki of 4.2 nmol/L against mouse cathepsin S while gabapentin is estimated at having an affinity of approximately 100 nmol/L (depending on splice variant) against the α2-1 subunit of voltagegated calcium channels (Lana et al., 2014) .
While MIV-247 was more potent (based on plasma levels) in this model of neuropathic pain, gabapentin and pregabalin displayed higher maximal efficacy. Gabapentin and pregabalin completely reversed mechanical allodynia while MIV-247 resulted in a maximal 50% reversal which was not further increased by raising the dose or by repeated dosing twice daily for 5 days. However, the doses of gabapentin and pregabalin required for maximal efficacy were close to doses associated with side effects which could confound anti-allodynic effects. approximately 50% reversal of mechanical hyperalgesia in a similar neuropathic pain model in rats (Clark et al., 2007; Irie et al., 2008) . The maximal effect in the current study was probably not due to saturable pharmacokinetic limitations since gradually higher doses of MIV-247 did give rise to higher exposures in the central nervous system and plasma without increasing efficacy. Hence, it appears as if at least a part of the developed mechanical allodynia in this model is independent of cathepsin S.
The first set of experiments demonstrated that gabapentin and pregabalin are agents with low potency (high plasma and CNS levels required) and a narrow therapeutic window but with an apparent high maximal efficacy. By contrast, MIV-247 was a highly potent agent with a wide therapeutic window while reaching a half-maximal effect. In addition, the agents most likely have different mechanisms of action with gabapentin/pregabalin reducing the release of nociceptive transmitters from the central terminals of primary afferent fibres whereas MIV-247 is presumed to reduce the facilitation of nociceptive transmission indirectly in the dorsal horn by inhibiting microglia activity. Considering these two distinct profiles, it was of interest to combine the two agents.
The magnitude of anti-allodynic efficacy was markedly increased when combining minimum effective doses of gabapentin/pregabalin and MIV-247 compared to when either agent was given alone. No significant effects on beam walking were detected in response to the combinations. Since we were able to achieve improved efficacy without detectable side effects, we combined the two agents at lower sub-effective doses. Interestingly, despite neither agent having any detectable efficacy when given alone, their combined effect was significant. For the MIV-247:pregabalin combination at sub-effective doses, anti-allodynic efficacy was significant at 3 h post-dose, whereas the sub-effective MIV-247:gabapentin combination resulted in significant efficacy at several time points post dose. Furthermore, the compounds did not seem to achieve their improved efficacy by interfering with each other´s pharmacokinetics since plasma and CNS exposures after the experiment appeared similar when given in combination as when given alone. Thus, it is highly likely that the improved efficacy is due to positive pharmacological interactions.
When combining two agents in preclinical pharmacological studies as done herein, a frequently asked question is if the combined effect is additive or synergistic. Often, investigators will construct so-called isobolograms by plotting dose levels of the two agents on the x-and y-axes respectively (see Tallarinda, 2006 for a review). Although the question is interesting for instance in a clinical study where only a few approved dosages of each compound can be given, we feel it is not relevant whether given oral doses of agents are synergistic or additive in preclinical studies like the current one. In preclinical studies, endless combinations can be given and the actual given dose is thus not of interest, the question should rather be whether the pharmacological effects per se may cause additive or synergistic effects. For that analysis to be made, one needs to know the actual concentration of test agent reaching the anticipated site of action. Since measuring compound levels in plasma or target tissue is seldom (if ever) measured in preclinical combination studies, a detailed analysis if two pharmacological actions are synergistic is beyond the scope of the current study. Instead, we considered it was more relevant to evaluate if a given combination enhanced efficacy without enhancing side effects or exposures of the agents. This seems to be achievable by combining agents like pregabalin and gabapentin with MIV-247 in the current study.
Preclinical data generated so far suggest that a major substrate for cathepsin S in the dorsal horn of the spinal cord is the chemokine fractalkine. Cathepsin S liberates soluble fractalkine and mechanical allodynia evoked by spinal administration of exogenous cathepsin S is abolished in mice lacking the CX3CR1 receptor which mediates fractalkine signaling (Clark et al., 2007; 2009) has been shown to activate PAR2 receptors (Reddy et al., 2010; Elmariah et al., 2014; Zhao et al., 2014) , and cathepsin S-induced colonic hyperalgesia in the periphery was suggested to be mediated via PAR2 receptors (Cattaruzza et al., 2011) . Less is known about PAR2 receptors in the spinal cord, but specific PAR2 receptor agonists cause mechanical and spinal hyperalgesia when administered intrathecally (Alier et al., 2008) , possibly via inhibition of inhibitory GABAergic neurotransmission (Huang et al., 2011) .
Given the multi-mechanistic nature of neuropathic pain, it is unlikely that one agent will be This article has not been copyedited and formatted. The final version may differ from this version. MIV-247 100 0.50 ± 0.0 8.7 ± 2.9 12 ± 3.7 13 ± 3. This article has not been copyedited and formatted. The final version may differ from this version. 
